Experimental Pill Nearly Doubles Survival Time for Advanced Pancreatic Cancer

Trial Results and Survival Rates

A novel daily pill called daraxonrasib has nearly doubled the survival time for patients with advanced pancreatic cancer, according to data presented at the American Society of Clinical Oncology’s (ASCO) annual meeting in Chicago. The clinical trial involved 500 patients with metastatic pancreatic cancer that had spread and stopped responding to previous treatments.

Patients who received daraxonrasib lived for a median of 13.2 months. In comparison, patients in the control group receiving chemotherapy survived for an average of 6.6 to 6.7 months. Researchers noted that while the drug does not cure the cancer, it represents a significant advancement in treatment options for one of the deadliest forms of the disease.

Drug Mechanism and Quality of Life

The pill is developed by pharmaceutical company Revolution Medicines and works by targeting and blocking a specific mutated gene associated with pancreatic cancer.

Beyond survival rates, trial participants reported fewer severe side effects compared to those receiving chemotherapy. Recipients of the drug also reported experiencing less pain and a better quality of life as their tumors shrank. While the effects of the pills eventually wane, patients were able to use daraxonrasib for significantly longer periods than the comparison group remained on chemotherapy.

Expert Reactions

The findings, which were published in the New England Journal of Medicine, were met with a standing ovation lasting nearly one minute from oncologists at the ASCO conference.

Dr. Zev Wainberg of the University of California, Los Angeles, who helped lead the study, described the results as "a very large step forward". Dr. Brian Wolpin of the Dana-Farber Cancer Institute, who presented the findings, stated that the drug should become "a new standard of care" for patients with previously treated metastatic pancreatic cancer.

Future Outlook

Researchers indicated that the survival gap between the two groups may widen as they continue to track participants, noting that many patients were still using the drug at the time the data was analyzed. Dr. Wolpin added that researchers will also explore further applications for the medication.